Previous 10 | Next 10 |
Richland WA, June 24, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) Vivos Inc announced that it has completed the first IsoPet ® therapy on an equoid tumor. It was administered at the University of Missouri on a horse that was transported from Ohio. This is an exciting ...
Richland, WA, May 27, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL). Vivos Inc. previously filed to extend its IsoPet ® trademark protection internationally. We are pleased to report that the Commissioner for Trademarks at the U.S. Patent and Trademark Office has conf...
Richland WA, May 24, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), During the past few months Vivos has made significant enhancements to the manufacturing process for Radiogel ™ . These enhancements are crucial in aligning with FDA requirements for future clinical tr...
Richland WA, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), provides 2020 recap and outlines future objectives. Vivos’ CEO, Dr. Mike Korenko stated, “as we begin 2021, I think it is important to review our progress during the past year and provide some...
Richland WA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Although we were unable to secure a Breakthrough Device Designation from the FDA, this was a well-designed process that considerably benefited Vivos Inc and provided us substantive and constructive feedback. ...
Richland WA, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce today that it worked with Mayo Clinic doctors to design and then conduct tests on the injection of hydrogel into spleens in mice. This conservative animal model was designed...
Richland WA, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL `` ), Vivos Inc (RDGL), a company that has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals and in humans, today announced that it will be presenting a...
Richland WA, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that it received the Patent Cooperation Treaty (PCT) International Search Report on our patent application (No.1811.191). We are excited to report that seven of our claims were imm...
Richland WA, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced that it has completed its submission to the FDA seeking Breakthrough Device Designation for Radiogel ™ . This is a voluntary program for certain medical devices that provide f...
Richland WA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce today that it is expanding Isopet ® into the equine market by making IsoPet ® available to treat solid tumors in horses. The most common tumors are equoids and sarcom...
News, Short Squeeze, Breakout and More Instantly...
The Dow Jones index closed higher by over 100 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern ar...
Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31 Hongchang International Co Ltd Com (New) (HCIL) is expected to report for Q4 2023 BioStem Technologies Inc (BSEM) is expected to report $0.47 for Q4 2023 Nicox SA (NICXF) is expected to report $-0.07 for Q4 2023 ...
Volcon Inc. (VLCN) is expected to report for Q4 2023 Tenaga Nasional Bhd ADR (TNABY) is expected to report for quarter end 2023-12-31 Hesai Group (HSAI) is expected to report for Q4 2023 Intrusion Inc. (INTZ) is expected to report $-0.14 for Q4 2023 Eliem Therapeutics Inc (ELYM) i...